Cargando…
Differential targeting of the cyclin-dependent kinase inhibitor, p21(CIP1/WAF1), by chelators with anti-proliferative activity in a range of tumor cell-types
Chelators such as 2-hydroxy-1-napthylaldehyde isonicotinoyl hydrazone (311) and di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) target tumor cell iron pools and inhibit proliferation. These agents also modulate multiple targets, one of which is the cyclin-dependent kinase inhibitor, p21...
Autores principales: | Moussa, Rayan S., Kovacevic, Zaklina, Richardson, Des R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745756/ https://www.ncbi.nlm.nih.gov/pubmed/26335183 |
Ejemplares similares
-
Reciprocal role of cyclins and cyclin kinase inhibitor p21(WAF1/CIP1 )on lymphocyte proliferation, allo-immune activation and inflammation
por: Khanna, Ashwani K
Publicado: (2005) -
The cyclin dependent kinase inhibitor p21(Cip1/Waf1) is a therapeutic target in high-risk neuroblastoma
por: Sorteberg, Agnes Luise, et al.
Publicado: (2022) -
Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
por: Harr, Michael W, et al.
Publicado: (2005) -
Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
por: Shi, Y., et al.
Publicado: (1996) -
The Role of the Cyclin Dependent Kinase Inhibitor p21(cip1/waf1) in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics
por: Al Bitar, Samar, et al.
Publicado: (2019)